By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) 

75 Sidney Street, 4th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-299-5000 Fax: 617-995-4995


Key Statistics

Ownership: Public

Web Site: AVEO Oncology
Symbol: AVEO


Merck & Co.  Cancer

Company News
AVEO Oncology (AVEO), Ophthotech Corporation (OPHT) Forge Research, License Deal Worth $105 Million+ 11/11/2014 7:03:37 AM
AVEO Oncology (AVEO) Reports Third Quarter 2014 Financial Results 11/6/2014 11:00:00 AM
AVEO Oncology (AVEO) And Biodesix, Inc. Announce Exploratory Analysis Of Veristrat-Selected Patients With Non-Small Cell Lung Cancer In Phase 2 Study Of Ficlatuzumab Presented At ESMO 2014 Congress 9/29/2014 12:17:49 PM
AVEO Oncology (AVEO) Announces Results From Phase 2 Clinical Studies Of Tivozanib In Patients With Advanced Colorectal And Kidney Cancers Presented At ESMO 2014 Congress 9/29/2014 11:37:32 AM
AVEO Oncology (AVEO) Terminates Cambridge Lease Agreement To Save $110 Million 9/26/2014 6:41:47 AM
Clinical Data On AVEO Oncology (AVEO)’s Ficlatuzumab And Tivozanib To Be Presented At The ESMO 2014 Congress 9/17/2014 12:54:59 PM
Ex-AVEO Oncology (AVEO) Executive Takes COO Job At Biotech Startup Scholar Rock 9/15/2014 6:33:25 AM
AVEO Oncology (AVEO) Reports Second Quarter 2014 Financial Results And Updates Progress On Strategic Plan 8/12/2014 8:39:00 AM
AVEO Oncology (AVEO) Announces Presentation Of AV-203 Phase 1 Results At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014 9:32:53 AM
AVEO Oncology (AVEO) To Present At The Jefferies and Co. Global Healthcare Conference 5/28/2014 7:24:54 AM